CorMedix Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for CorMedix Inc. (CRMD) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-17.93-46.34-29.70-28.21-22.03-16.43-26.83
Depreciation & Amortization0.310.210.080.060.160.390.07
Stock Based Compensation6.135.494.075.042.500.000.00
Change in Working Capital-39.412.371.071.84-2.63-1.911.94
Change in Accounts Receivable-51.790.000.04-0.040.000.000.00
Change in Inventory-5.49-2.110.000.150.150.000.00
Change in Accounts Payable-2.562.08-0.011.080.100.000.00
Change in Other Working Capital0.150.130.120.12-2.890.000.00
Other Operating Activities0.155.360.120.122.522.903.13
Net Cash from Operating Activities-50.61-38.41-24.36-21.16-21.97-15.05-23.70
Investing Activities
Capital Expenditures-0.12-0.33-0.22-1.430.110.04-0.05
Purchases of Investments-26.77-77.08-31.14-15.297.540.000.00
Sales/Maturities of Investments48.1260.3527.657.587.54-11.981.60
Net Cash from Investing Activities21.23-17.06-3.71-9.137.43-12.021.56
Financing Activities
Common Stock Issued18.8855.8317.7741.4639.6915.2321.97
Common Stock Repurchased0.00-0.200.000.000.000.000.00
Other Financing Activities-0.29-0.200.000.000.00-0.23-0.11
Net Cash from Financing Activities26.3255.9217.9041.7640.1025.8029.40
Summary
Effect of Forex Changes on Cash0.000.00-0.01-0.010.010.00-0.01
Net Change in Cash-3.070.45-10.1711.4725.57-1.277.25
Cash at Beginning of Period43.8243.3753.5542.1016.5317.8010.55
Cash at End of Period40.76-38.4143.3753.5542.1016.5317.80
Free Cash Flow-50.73-38.41-24.58-22.58-22.08-15.09-23.75
Supplemental Disclosures
Interest Paid0.040.030.030.020.030.010.00